Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes

Conclusion: Dapagliflozin seemingly influences systemic and renal hemodynamics independently and beyond glucose lowering in people with type 2 diabetes. This clinical trial was registered at https://clinicalTrials.gov (ID: NCT02682563).
Source: Journal of Hypertension - Category: Cardiology Tags: ORIGINAL PAPERS: Treatment Source Type: research